Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Pang

Showing results (781-790 of 824) with videos related to

Pageof 83
Sort By:
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J Corley, Maya Watanabe, Alina P S Pang, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
Journal of Cardiac Failure|October 11, 2023
Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF TrialDaniela Tomasoni, Beth Davison, Marianna Adamo, et al.
The Journal of Pathology|December 13, 2017
EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinomaRaymond W-M Lung, Pok-Man Hau, Ken H-O Yu, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
European Heart Journal|May 22, 2023
NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trialMarianna Adamo, Matteo Pagnesi, Alexandre Mebazaa, et al.
JAMA Cardiology|December 27, 2023
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical TrialGad Cotter, Benjamin Deniau, Beth Davison, et al.
Pageof 83

Showing results (781-790 of 824) with videos related to

Sort By:
Pageof 83
The Lancet. Infectious Diseases|February 25, 2016
Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trialMichael Manns, Didier Samuel, Edward J Gane, et al.
The Lancet. Infectious Diseases|April 13, 2015
Ledipasvir and sofosbuvir fixed-dose combination with and without ribavirin for 12 weeks in treatment-naive and previously treated Japanese patients with genotype 1 hepatitis C: an open-label, randomised, phase 3 trialMasashi Mizokami, Osamu Yokosuka, Tetsuo Takehara, et al.
The Lancet. Infectious Diseases|March 17, 2015
Ledipasvir-sofosbuvir with or without ribavirin to treat patients with HCV genotype 1 infection and cirrhosis non-responsive to previous protease-inhibitor therapy: a randomised, double-blind, phase 2 trial (SIRIUS)Marc Bourlière, Jean-Pierre Bronowicki, Victor de Ledinghen, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|June 27, 2025
Effect of Pitavastatin on Epigenetic Aging Biomarkers in People With HIV: Pilot Substudy of the REPRIEVE TrialMichael J Corley, Maya Watanabe, Alina P S Pang, et al.
JACC. Heart Failure|November 29, 2020
Effects of a Novel Nitroxyl Donor in Acute Heart Failure: The STAND-UP AHF StudyG Michael Felker, John J V McMurray, John G Cleland, et al.
Journal of Cardiac Failure|October 11, 2023
Safety Indicators in Patients Receiving High-intensity Care After Hospital Admission for Acute Heart Failure: The STRONG-HF TrialDaniela Tomasoni, Beth Davison, Marianna Adamo, et al.
The Journal of Pathology|December 13, 2017
EBV-encoded miRNAs target ATM-mediated response in nasopharyngeal carcinomaRaymond W-M Lung, Pok-Man Hau, Ken H-O Yu, et al.
JAMA|February 24, 2015
Virologic response following combined ledipasvir and sofosbuvir administration in patients with HCV genotype 1 and HIV co-infectionAnu Osinusi, Kerry Townsend, Anita Kohli, et al.
European Heart Journal|May 22, 2023
NT-proBNP and high intensity care for acute heart failure: the STRONG-HF trialMarianna Adamo, Matteo Pagnesi, Alexandre Mebazaa, et al.
JAMA Cardiology|December 27, 2023
Optimization of Evidence-Based Heart Failure Medications After an Acute Heart Failure Admission: A Secondary Analysis of the STRONG-HF Randomized Clinical TrialGad Cotter, Benjamin Deniau, Beth Davison, et al.
Pageof 83